Cytotoxic and targeted therapy for BRCA1/2-driven cancers

Hereditary Cancer in Clinical Practice

Evgeny N. Imyanitov¹ 

[1] N.N. Petrov Institute of Oncology, Pesochny, 197758, Saint-Petersburg, Russia;St.-Petersburg Pediatric Medical University, 194100, Saint Petersburg, Russia;I.I. Mechnikov North-Western Medical University, 191015, St.-Petersburg, Russia;

关键词: BRCA1;    BRCA2;    Cisplatin;    Carboplatin;    Mitomycin C;    PARP inhibitors;    BRCAness;   

DOI  :  10.1186/s13053-021-00193-y

来源: Springer

【 摘 要 】

Tumors arising in BRCA1/2 germline mutation carriers usually demonstrate somatic loss of the remaining BRCA1/2 allele and increased sensitivity to platinum compounds, anthracyclines, mitomycin C and poly (ADP-ribose) polymerase inhibitors (PARPi). Exposure to conventional platinum-based therapy or PARPi results in the restoration of BRCA1/2 function and development of resistance to systemic therapy, therefore, there is a need for other treatment options. Some studies suggested that the use of specific drug combinations or administration of high-dose chemotherapy may result in pronounced tumor responses. BRCA1/2-driven tumors are characterized by increased immunogenicity; promising efficacy of immune therapy has been demonstrated in a number of preclinical and clinical investigations. There are outstanding issues, which require further consideration. Platinum compounds and PARPi have very similar mode of antitumor action and are likely to render cross-resistance to each other, so their optimal position in cancer treatment schemes may be a subject of additional studies. Sporadic tumors with somatically acquired inactivation of BRCA1/2 or related genes resemble hereditary neoplasms with regard to the spectrum of drug sensitivity; the development of user-friendly BRCAness tests presents a challenge. Many therapeutic decisions are now based on the BRCA1/2 status, so the significant reduction of the turn-around time for predictive laboratory assays is of particular importance.

【 授权许可】

CC BY